FULCRUM THERAPEUTICS, INC. Accumulated Other Comprehensive Income
FULCRUM THERAPEUTICS, INC. (FULC) had Accumulated Other Comprehensive Income of -$567.00 thousand as of 2026-06-30, per its S-4 filed 2026-09-02.
Financial Statements › Balance Sheet › Equity › Equity, Attributable to Parent
us-gaap:AccumulatedOtherComprehensiveIncomeLossNetOfTax · last filed 2026-09-02
- 2026-06-30: Accumulated Other Comprehensive Income (Loss), Net of Tax -$567.00K.
- 2026-03-31: Accumulated Other Comprehensive Income (Loss), Net of Tax -$513.00K.
- 2025-12-31: Accumulated Other Comprehensive Income (Loss), Net of Tax $174.00K.
- 2025-09-30: Accumulated Other Comprehensive Income (Loss), Net of Tax $241.00K.
| Period end | Accumulated Other Comprehensive Income (Loss), Net of Tax |
|---|---|
| 2026-06-30 | -$567.00K S-4 · filed 2026-09-02 |
| 2026-03-31 | -$513.00K 10-Q · filed 2026-04-27 |
| 2025-12-31 | $174.00K S-4 · filed 2026-09-02 |
| 2025-09-30 | $241.00K 10-Q · filed 2025-10-29 |
| 2025-06-30 | $82.00K 10-Q · filed 2025-07-29 |
| 2025-03-31 | $70.00K 10-Q · filed 2025-05-01 |
| 2024-12-31 | $130.00K S-4 · filed 2026-09-02 |
| 2024-09-30 | $379.00K 10-Q · filed 2024-11-13 |
| 2024-06-30 | -$366.00K 10-Q · filed 2024-07-31 |
| 2024-03-31 | -$434.00K 10-Q · filed 2024-05-13 |
| 2023-12-31 | -$136.00K 10-K · filed 2025-02-25 |
| 2023-09-30 | -$886.00K 10-Q · filed 2023-11-07 |
| 2023-06-30 | -$1.20M 10-Q · filed 2023-08-03 |
| 2023-03-31 | -$651.00K 10-Q · filed 2023-05-15 |
| 2022-12-31 | -$797.00K 10-K · filed 2024-02-27 |
| 2022-09-30 | -$921.00K 10-Q · filed 2022-11-08 |
| 2022-06-30 | -$1.07M 10-Q · filed 2022-08-11 |
| 2022-03-31 | -$1.09M 10-Q · filed 2022-05-09 |
| 2021-12-31 | -$397.00K 10-K/A · filed 2023-06-26 |
| 2021-09-30 | -$87.00K 10-Q · filed 2021-11-04 |
| 2021-06-30 | -$9.00K 10-Q · filed 2021-08-10 |
| 2021-03-31 | -$4.00K 10-Q · filed 2021-05-06 |
| 2020-12-31 | -$2.00K 10-K/A · filed 2023-06-26 |
| 2020-09-30 | $31.00K 10-Q · filed 2020-11-10 |
| 2020-06-30 | $81.00K 10-Q · filed 2020-08-11 |
| 2020-03-31 | -$53.00K 10-Q · filed 2020-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Mereo BioPharma Group plc (MREO) | $0.269B | -9.41 | |
| Greenwich LifeSciences, Inc. (GLSI) | United States | $0.267B | -15.02 |